Cantor Fitzgerald raises Eli Lilly stock price target on strong outlook

Cantor Fitzgerald raised Eli Lilly’s price target to $1,350 from $1,230 while keeping an Overweight rating, arguing 2Q26 results for large-cap biopharma should be broadly strong and drive FY26 top-line guidance raises. The stock is up ~57% from the prior reported period (56.6% over the past year), trading around $1,213.91 near its $1,238 52-week high, with the article noting only slight overvaluation vs fair value. Regulatory updates include EMA’s positive opinion for Jaypirca and Sandoz’s FDA generic tirzepatide applications, alongside plans for Lilly’s Europe/UK weight-loss pill launch by early 2027.

Analysis

The near-term setup is less about a new fundamental inflection and more about positioning: large-cap biopharma is catching a factor bid as investors rotate out of AI, and that usually supports the highest-quality, most liquid names first. For LLY, that can extend momentum, but it also means the stock is being asked to absorb perfection at a valuation that already discounts a lot of future obesity upside. In that regime, the first real test is not the analyst target hike itself; it is whether the next earnings/guidance print confirms enough incremental growth to justify further multiple expansion.

Competitive dynamics matter more in the medium term. The tirzepatide generic filing is not a near-term earnings event, but it is a ceiling on terminal valuation because it signals that the market will eventually start pricing obesity-margin compression years before actual sales are hit. That risk is asymmetric for LLY versus ABBV: ABBV can participate in the sector rerating without a single-product overhang, so on a relative basis it should be more resilient if the market’s enthusiasm shifts from "growth at any price" to "durable cash flow plus guidance visibility."

The contrarian point is that the consensus may be over-crediting fundamentals when the primary driver is still macro/flow. If AI leadership resumes or rates back up, the sector’s multiple support can fade quickly even if Q2 numbers are good. The thesis is falsified if LLY delivers a material FY26 guide raise that shows pricing/volume still outpaces expectations; conversely, if the next print is merely in line, this rally is vulnerable to a 1-2 month mean reversion.

Key Decisions for Investors

• Relative value: long ABBV / short LLY for 1-3 months. Rationale: ABBV gets the sector rerating with less single-asset risk, while LLY is more exposed to valuation compression if the obesity/generic narrative becomes the focus. Falsify if LLY raises FY26 revenue guidance materially above consensus on the next print.
• Do not chase LLY after the gap higher; wait for post-earnings or a 3-5% pullback to add exposure. At current levels the risk/reward is skewed because the stock is already pricing in a strong guidance cycle and little execution slippage.
• If you want to express the sector view, prefer IBB/XBI over single-name LLY for the next 1-2 quarters. The basket captures the rotation trade without paying peak multiple for the most crowded winner.
• Treat SDZNY as a watchlist, not a trade, until there is an actual FDA approval timeline and manufacturing/legal clarity. The generic tirzepatide filing is an overhang on LLY’s terminal multiple, but it is too distant to underwrite an outright long in the name today.